Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05873634 · ClinicalTrials.gov registry record

HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

A clinical trial of Heart Failure and Heart Failure With Preserved Ejection Fraction, sponsored by Northwestern University.

Recruiting
Registry status
1,000
Enrollment target
6
Study locations

NCT05873634: Recruiting study of Heart Failure and Heart Failure With Preserved Ejection Fraction, sponsored by Northwestern University.

NCT05873634 is a study of Heart Failure and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 1,000 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (51% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05873634, a study of Heart Failure and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
1,000 participants
Enrollment target
6
Study locations

Study Summary

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

Study Locations (6)

California

  • University of California Davis - Sacramento

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Mass General Brigham - Boston

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • Wake Forest University - Winston-Salem

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-03-01
Est. Completion 2026-06
Northwestern University

1,209 total trials

What NCT05873634 shows while recruiting

NCT05873634 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (51% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.

NCT05873634 lists 6 locations in 6 states (California, Illinois, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT05873634 about?

NCT05873634 is a clinical study titled "HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets". HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes t...

What is the current status of trial NCT05873634?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-03-01. Estimated completion is 2026-06.

What conditions does trial NCT05873634 study?

This clinical trial studies the following conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction.

Who is sponsoring clinical trial NCT05873634?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05873634 being conducted?

This trial has 6 study locations across California, Illinois, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05873634's enrollment target sits among peer trials

1,000 67th of 397 higher than 325 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05873634, the US trial registry maintained by the National Library of Medicine. NCT05873634 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.